JP2011516417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516417A5 JP2011516417A5 JP2011501153A JP2011501153A JP2011516417A5 JP 2011516417 A5 JP2011516417 A5 JP 2011516417A5 JP 2011501153 A JP2011501153 A JP 2011501153A JP 2011501153 A JP2011501153 A JP 2011501153A JP 2011516417 A5 JP2011516417 A5 JP 2011516417A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- disease
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4008708P | 2008-03-27 | 2008-03-27 | |
| US61/040,087 | 2008-03-27 | ||
| PCT/EP2009/002241 WO2009118187A1 (en) | 2008-03-27 | 2009-03-26 | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014020051A Division JP2014098018A (ja) | 2008-03-27 | 2014-02-05 | Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516417A JP2011516417A (ja) | 2011-05-26 |
| JP2011516417A5 true JP2011516417A5 (enExample) | 2012-01-05 |
Family
ID=40910288
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501153A Pending JP2011516417A (ja) | 2008-03-27 | 2009-03-26 | Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
| JP2014020051A Pending JP2014098018A (ja) | 2008-03-27 | 2014-02-05 | Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
| JP2015236571A Pending JP2016094430A (ja) | 2008-03-27 | 2015-12-03 | Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014020051A Pending JP2014098018A (ja) | 2008-03-27 | 2014-02-05 | Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
| JP2015236571A Pending JP2016094430A (ja) | 2008-03-27 | 2015-12-03 | Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110053951A1 (enExample) |
| EP (1) | EP2254580A1 (enExample) |
| JP (3) | JP2011516417A (enExample) |
| KR (1) | KR20100135847A (enExample) |
| CN (1) | CN101977606A (enExample) |
| AU (1) | AU2009228660B2 (enExample) |
| BR (1) | BRPI0909378A2 (enExample) |
| CA (1) | CA2719749A1 (enExample) |
| IL (1) | IL207835A0 (enExample) |
| MX (1) | MX2010009649A (enExample) |
| NZ (1) | NZ588698A (enExample) |
| RU (1) | RU2499598C2 (enExample) |
| WO (1) | WO2009118187A1 (enExample) |
| ZA (1) | ZA201006587B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013251079B2 (en) | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| WO2015175806A1 (en) | 2014-05-16 | 2015-11-19 | The Trustees Of The University Of Pennsylvania | Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models |
| JP6605020B2 (ja) | 2014-08-15 | 2019-11-13 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール |
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| CN107849010B (zh) | 2015-06-01 | 2021-11-09 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的3,3‐二氟哌啶氨基甲酸酯杂环化合物 |
| SMT202000134T1 (it) | 2015-07-09 | 2020-05-08 | Janssen Pharmaceutica Nv | 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| US10732235B2 (en) * | 2018-03-29 | 2020-08-04 | Siemens Healthcare Gmbh | Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping |
| JP7346441B2 (ja) | 2018-04-04 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用 |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| CA3142998A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as glun2b receptor modulators |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| US11618750B2 (en) | 2019-06-14 | 2023-04-04 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| CA3143102A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199801774T2 (xx) * | 1996-03-08 | 1998-12-21 | F.Hoffmann-La Roche Ag | 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�. |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) * | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| DK1070708T3 (da) * | 1999-07-21 | 2004-05-10 | Hoffmann La Roche | Triazolderivater |
| EP1278728B1 (en) * | 2000-04-20 | 2004-08-25 | F. Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| US6432985B2 (en) * | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| AU2001296994A1 (en) * | 2000-10-06 | 2002-04-15 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| EP1915624A1 (en) * | 2005-07-29 | 2008-04-30 | Regents of the University of Minnesota | Amyloid beta receptor and uses thereof |
-
2009
- 2009-03-26 BR BRPI0909378A patent/BRPI0909378A2/pt not_active IP Right Cessation
- 2009-03-26 KR KR1020107023896A patent/KR20100135847A/ko not_active Ceased
- 2009-03-26 NZ NZ588698A patent/NZ588698A/en not_active IP Right Cessation
- 2009-03-26 CN CN2009801104274A patent/CN101977606A/zh active Pending
- 2009-03-26 RU RU2010143864/15A patent/RU2499598C2/ru not_active IP Right Cessation
- 2009-03-26 MX MX2010009649A patent/MX2010009649A/es active IP Right Grant
- 2009-03-26 EP EP09724248A patent/EP2254580A1/en not_active Withdrawn
- 2009-03-26 CA CA2719749A patent/CA2719749A1/en not_active Abandoned
- 2009-03-26 WO PCT/EP2009/002241 patent/WO2009118187A1/en not_active Ceased
- 2009-03-26 JP JP2011501153A patent/JP2011516417A/ja active Pending
- 2009-03-26 AU AU2009228660A patent/AU2009228660B2/en not_active Ceased
- 2009-03-26 US US12/919,804 patent/US20110053951A1/en not_active Abandoned
-
2010
- 2010-08-26 IL IL207835A patent/IL207835A0/en unknown
- 2010-09-14 ZA ZA2010/06587A patent/ZA201006587B/en unknown
-
2014
- 2014-02-05 JP JP2014020051A patent/JP2014098018A/ja active Pending
-
2015
- 2015-12-03 JP JP2015236571A patent/JP2016094430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516417A5 (enExample) | ||
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| JP2013525444A5 (enExample) | ||
| US11987589B2 (en) | Heterocyclic flavone derivatives, compositions, and methods related thereto | |
| JP2015501783A5 (enExample) | ||
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| JP2016185995A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| JP2013507352A5 (enExample) | ||
| WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
| EA201000384A1 (ru) | Новая полиморфная форма ротиготина и способ её получения | |
| JP2013533287A5 (enExample) | ||
| JP2012523395A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| JP2011505356A5 (enExample) | ||
| JP2019512469A5 (enExample) | ||
| RU2009135016A (ru) | Твердые формы, содержащие (-)-о-десметилвенлафаксин, и их применения | |
| MX2011008627A (es) | Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos. | |
| JP5842058B2 (ja) | 自閉症の治療における使用のためのクレンブテロール | |
| TW201420133A (zh) | 針對嚴重頭痛之普拉克索的經皮遞送 | |
| JP2013536837A5 (enExample) |